1-7. (canceled)
8. A device for switching a swivelable holder between two positions comprising:
a rotatable actuating element, said swivelable holder having a stop for each position; and
two stretchable connection elements being provided, each of which being articulated at said actuating element and at the swivelable holder at a distance from axes of rotation of said holder, wherein the articulation points are located essentially opposite one another with respect to the axes of rotation.
9. The device for switching a swivelable holder according to claim 1, wherein the axes of rotation of the swivelable holder and of the actuating element are directed substantially parallel to one another.
10. The device for switching a swivelable holder according to claim 1, wherein the axes of rotation of the swivelable holder and of the actuating element extend substantially at an angle of 90\xb0 relative to one another.
11. The device for switching a swivelable holder according to claim 1, wherein the actuating element preferably has a catch.
12. The device for switching a swivelable holder according to claim 1, wherein the two stretchable connection elements extend substantially parallel to one another.
13. The device for switching a swivelable holder according to claim 1, wherein the stretchable connection elements are constructed as springs.
14. The device for switching a swivelable holder according to claim 1, wherein the stretchable connection elements are constructed as elastic cables.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition comprising a homogeneous solution of a desoxyepothilone together with a pharmaceutically acceptable carrier, said pharmaceutically acceptable carrier comprising one or more components selected from the group consisting of alcohols, glycols, polyoxyethylene sorbitan monoesters, poly(C2-C3)alkylene glycols, and Solutol\xae HS-15, wherein the pharmaceutical composition provides physically and chemically stable solutions before and after dilution into aqueous medium.
2. The pharmaceutical composition of claim 1, wherein said desoxyepothilone is present at between about 0.1 mgmL and about 100 mgmL, and wherein the pharmaceutically acceptable carrier comprises ethanol, glycerol, a polyethylene glycol, and a polyoxyethylene sorbitan monoester.
3. The pharmaceutical composition of claim 2, wherein said pharmaceutically acceptable carrier comprises ethanol at between about 40% and about 70%, glycerol at between about 5% and about 15%, PEG 400 at between about 10% and about 40%, and polysorbate 80 at between about 5% and about 15%.
4. The pharmaceutical composition of claim 3, wherein said pharmaceutically acceptable carrier comprises ethanol at about 60%, glycerol at about 10%, PEG 400 at about 20%, and polysorbate 80 at about 10%.
5. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition comprises epothilone D at between about 1 mgmL and about 20 mgmL.
6. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition comprises epothilone D at between about 1 mgmL and about 10 mgmL.
7. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition comprises epothilone D at about 10 mgmL.
8. The pharmaceutical composition of claim 1, wherein said desoxyepothilone is present at between about 1 mgmL and about 100 mgmL, and wherein said pharmaceutically acceptable carrier comprises ethanol, propylene glycol, PEG400, and polysorbate 80.
9. The pharmaceutical composition of claim 8, wherein said pharmaceutically acceptable carrier comprises ethanol at between about 40% and about 70%, propylene glycol at between about 5% and about 15%, PEG400 at between about 10% and about 40%, and polysorbate 80 at between about 5% and about 15%.
10. The pharmaceutical composition of claim 9, wherein said pharmaceutically acceptable carrier comprises ethanol at about 50%, propylene glycol at about 10%, PEG400 at about 30%, and polysorbate 80 at about 10%.
11. The pharmaceutical composition of claim 10, wherein said pharmaceutical composition comprises epothilone D at between about 1 mgmL and about 20 mgmL.
12. The pharmaceutical composition of claim 10, wherein said pharmaceutical composition comprises epothilone D at between about 1 mgmL and about 10 mgmL.
13. The pharmaceutical composition of claim 10, wherein said pharmaceutical composition comprises epothilone D at about 10 mgmL.
14. The pharmaceutical composition of claim 1, wherein said desoxyepothilone is present at between about 1 mgmL and about 100 mgmL, and wherein said pharmaceutically acceptable carrier comprises ethanol, PEG400, and Solutol HS-15.
15. The pharmaceutical composition of claim 14, wherein said pharmaceutically acceptable carrier comprises ethanol at between about 40% and about 70%, PEG400 at between about 10% and about 40%, and Solutol HS-15 at between about 10% and about 30%.
16. The pharmaceutical composition of claim 15, wherein said pharmaceutically acceptable carrier comprises ethanol at about 50%, PEG400 at about 30%, and Solutol HS-15 at about 20%.
17. The pharmaceutical composition of claim 16, wherein said pharmaceutical composition comprises epothilone D at between about 1 mgmL and about 20 mgmL.
18. The pharmaceutical composition of claim 16, wherein said pharmaceutical composition comprises epothilone D at between about 1 mgmL and about 10 mgmL.
19. The pharmaceutical composition of claim 16, wherein said pharmaceutical composition comprises epothilone D at about 10 mgmL.
20. A method for treating a proliferative disease sensitive to treatment with a desoxyepothilone to a subject in need of such treatment, which method comprises
(a) diluting a pharmaceutical composition according to claim 1 with an aqueous medium to form an infusion solution; and
(b) administering the infusion solution parenterally to the subject so as to provide a therapeutically effective dose of the desoxyepothilone.